Efficacy of pembrolizumab (pembro) monotherapy versus chemotherapy for PD-L1-positive (CPS ≥10) advanced G/GEJ cancer in the phase II KEYNOTE-059 (cohort 1) and phase III KEYNOTE-061 and KEYNOTE-062 studies

被引：0

作者：

Wainberg, Zev A.

Fuchs, Charles S.

Tabernero, Josep

Shitara, Kohei

Muro, Kei

Van Cutsem, Eric

Bang, Yung-Jue

Chung, Hyun Cheol

Yamaguchi, Kensei

Varga, Eniko

Chen, Jen-Shi

Hochhauser, Daniel

Thuss-Patience, Peter C.

Al-Batran, Salah-Eddin

Garrido, Marcelo

Kher, Uma

Shih, Chie-Schin

Shah, Sukrut

Bhagia, Pooja

Chao, Joseph

机构：

[1] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA

[2] Smilow Canc Hosp, Yale Canc Ctr, New Haven, CT USA

[3] Vall dHebron Univ Hosp, Barcelona, Spain

[4] Vall dHebron Inst Oncol, Barcelona, Spain

[5] Natl Canc Ctr Hosp East, Chiba, Japan

[6] Canc Ctr Hosp, Dept Clin Oncol, Nagoya, Aichi, Japan

[7] Univ Hosp, Leuven, Belgium

[8] Katholieke Univ Leuven, Leuven, Belgium

[9] Seoul Natl Univ Hosp, Seoul, South Korea

[10] Yonsei Univ, Coll Med, Yonsei Canc Ctr, Seoul, South Korea

[11] JFCR, Canc Inst Hosp, Tokyo, Japan

[12] Debreceni Egyet Klin Kozpont, Debrecen, Hungary

[13] Linkou Chang Gung Mem Hosp, Taoyuan, Taiwan

[14] UCL Hosp NHS Fdn Trust, London, England

[15] Charite Campus Virchow Klinikum, Berlin, Germany

[16] Inst Klin Onkol, Frankfurt, Germany

[17] Pontificia Univ Catolica Chile, Santiago, Chile

[18] Merck & Co Inc, Kenilworth, NJ USA

[19] City Hope Comprehens Canc Ctr, Duarte, CA USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 04期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

427

引用

页数：2

共 50 条

[21] Final analysis of the phase III KEYNOTE-042 study: Pembrolizumab (Pembro) versus platinum-based chemotherapy (Chemo) as first-line therapy for patients (Pts) with PD-L1-positive locally advanced/metastatic NSCLC
Mok, T. S. K.
Wu, Y-L.
Kudaba, I.
Kowalski, D. M.
Cho, B. C.
Turna, H. Z.
de Castro, G., Jr.
Srimuninnimit, V.
Laktionov, K. K.
Bondarenko, I.
Kubota, K.
Caglevic, C.
Karaszewska, B.
Dang, T.
Yin, L.
Penrod, J.
Lopes, G.
ANNALS OF ONCOLOGY, 2019, 30 : 38 - 38
[22] Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1 positive advanced non small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies
Nosaki, Kaname
Saka, Hideo
Hosomi, Yukio
Baas, Paul
de Castro, Gilberto, Jr.
Reck, Martin
Wu, Yi-Long
Brahmer, Julie R.
Felip, Enriqueta
Sawada, Takeshi
Noguchi, Kazuo
Han, Shi Rong
Piperdi, Bilal
Kush, Debra A.
Lopes, Gilberto
LUNG CANCER, 2019, 135 : 188 - 195
[23] KEYNOTE-062 First randomized Phase-III-Study for Examination of PD-1 Antibody as Monotherapy as well as in Combination with Chemotherapy for First-line Treatment of these Patients
不详
VISCERAL MEDICINE, 2019, 35 (04) : 279 - 279
[24] Quality of life with first-line pembrolizumab for PD-L1epositive advanced gastric/gastroesophageal junction adenocarcinoma: results from the randomised phase III KEYNOTE-062 study
Van Cutsem, E.
Valderrama, A.
Bang, Y. -J.
Fuchs, C. S.
Shitara, K.
Janjigian, Y. Y.
Qin, S.
Larson, T. G.
Shankaran, V.
Stein, S.
Norquist, J. M.
Kher, U.
Shah, S.
Alsina, M.
ESMO OPEN, 2021, 6 (04)
[25] KEYNOTE-086 cohort B: Pembrolizumab monotherapy for PD-L1-positive, previously untreated, metastatic triple-negative breast cancer (mTNBC)
Adams, Sylvia
Loi, Sherene
Toppmeyer, Deborah L.
Cescon, David W.
De laurentiis, Michele
Nanda, Rita
Winer, Eric P.
Mukai, Hirofumai
Tamura, Kenji
Armstrong, Anne C.
Liu, Minetta C.
Iwata, Hiroji
Ryvo, Larisa
Wimberger, Pauline
Rugo, Hope S.
Tan, Antoinette
D'Aquanno, Christine
Ding, Yu
Karantza, Vassiliki
Schmid, Peter
CANCER RESEARCH, 2018, 78 (04)
[26] KEYNOTE-051: An update on the phase 2 results of pembrolizumab (pembro) in pediatric patients (pts) with advanced melanoma or a PD-L1-positive advanced, relapsed or refractory solid tumor or lymphoma.
Geoerger, Birgit
Kang, Hyoung Jin
Yalon-Oren, Michal
Marshall, Lynley V.
Vezina, Catherine
Pappo, Alberto S.
Laetsch, Theodore Willis
Petrilli, Antonio Sergio
Ebinger, Martin
Toporski, Jacek
Glade-Bender, Julia
Nicholls, Wayne
Fox, Elizabeth
DuBois, Steven G.
Macy, Margaret
Cohn, Susan Lerner
Pathiraja, Kumudu
Diede, Scott J.
Ebbinghaus, Scot
Pinto, Navin R.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[27] KEYNOTE-059 cohort 2: Safety and efficacy of pembrolizumab (pembro) plus 5-fluorouracil (5-FU) and cisplatin for first-line (1L) treatment of advanced gastric cancer.
Bang, Yung-Jue
Muro, Kei
Fuchs, Charles S.
Golan, Talia
Geva, Ravit
Hara, Hiroki
Jalal, Shadia Ibrahim
Borg, Christophe
Doi, Toshihiko
Wainberg, Zev A.
Wang, Jiangdian
Koshiji, Minori
Dalai, Rita P.
Chung, Hyun Cheol
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[28] Pembrolizumab in Paediatric Patients with Advanced Melanoma or A PD-L1-Positive (PD-L1+) Advanced, Relapsed, or Refractory Solid Tumour or Lymphoma: Phase 1/2 Keynote-051 Study
Geoerger, B.
Fox, E.
Pappo, A.
Yalon-Oren, M.
Marshall, V.
Vezina, C.
Pathiraja, K.
Diede, S. J.
Ebbinghaus, S.
Park, J. R.
PEDIATRIC BLOOD & CANCER, 2016, 63 : S195 - S195
[29] Associations of tissue tumor mutational burden and mutational status with clinical outcomes in KEYNOTE-042: pembrolizumab versus chemotherapy for advanced PD-L1-positive NSCLC
Mok, T. S. K.
Lopes, G.
Cho, B. C.
Kowalski, D. M.
Kasahara, K.
Wu, Y. -l.
de Castro Jr, G.
Turna, H. Z.
Cristescu, R.
Aurora-Garg, D.
Loboda, A.
Lunceford, J.
Kobie, J.
Ayers, M.
Pietanza, M. C.
Piperdi, B.
Herbst, R. S.
ANNALS OF ONCOLOGY, 2023, 34 (04) : 377 - 388
[30] Pembrolizumab vs paclitaxel as second-line treatment for Asian patients with PD-L1-positive advanced gastric or gastroesophageal cancer (GC) in the phase III KEYNOTE-063 trial.
Chung, Hyun Cheol
Kang, Yoon-Koo
Chen, Zhendong
Bai, Yuxian
Ishak, Wan Zamaniah Wan
Shim, Byoung Yong
Park, Youngiee
Koo, Dong-Hoe
Lu, Jin Wei
Xu, Jianming
Bhagia, Pooja
Kuang, Shu
Shih, Chie-Schin
Qin, Shukui
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)

← 1 2 3 4 5 →